BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineHematology & OncologyPathologyPharmacyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerUterine CancerCancerChemotherapyHealth TechnologyGenetics
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, April 1, 2019 (HealthDay News) -- For patients with FMS-like tyrosine kinase 3 (FLT3) mutations who have relapsed or refractory acute myeloid leukemia (AML), gilteritinib results in longer overall survival and higher response rates than salvage chemotherapy (SC), according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 29 to April 3 in Atlanta.
Alexander E. Perl, M.D., from the Abramson Cancer Center at the University of Pennsylvania in Philadelphia, and colleagues randomly assigned adults with confirmed FLT3mut+ AML refractory to induction chemotherapy or in untreated first relapse to receive either continuous 28-day cycles of 120 mg/day gilteritinib (247 patients) or SC (124 patients).
The researchers found that patients assigned to gilteritinib had significantly longer overall survival (9.3 versus 5.6 months; hazard ratio for death, 0.637; P = 0.0007); survival rates at one year were 37.1 and 16.7 percent, respectively. The rates of complete remission/complete remission with partial hematologic recovery (CR/CRh) were 34.0 and 15.3 percent for gilteritinib and SC, respectively (P = 0.0001); CR rates were 21.1 and 10.5 percent (P = 0.0106). For the gilteritinib and SC arms, median event-free survival was 2.8 and 0.7 months, respectively (hazard ratio, 0.793; P = 0.0830). Per patient-year, serious treatment-emergent adverse events were less common with gilteritinib than SC.
"Across the board, this trial shows gilteritinib carries a clear survival benefit, meaning we now have a targeted, highly-effective, and well-tolerated treatment option for a group of truly high-risk patients," Perl said in a statement.
Gilteritinib is manufactured by Astellas Pharma, which funded the study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 27, 2022
Read this Next
Other Trending Articles